Onchocerciasis or river blindness is the world's
second leading infectious cause of blindness. It is
caused by Onchocerca volvulus, a parasitic worm that
can live for up to fourteen years in the human body.
Life cycle
The life cycle of O. volvulus begins when a parasitised
female black fly of the genus Simulium takes a blood meal.
Saliva containing stage three O. volvulus larvae
passes into the blood. From here the larvae migrate to the
subcutaneous tissue where they form nodules and then mature
into adult worms over a period of one to three months.
After the worms have matured they mate, the female worm
producing between 1000 and 1900 eggs per day. The eggs
mature internally to form stage one microfilariae , which
are released from the female's body one at a time.
The microfilariae migrate from the location of the nodule to
the skin where they wait to be taken up by a black fly.
Once in the black fly they moult twice within seven days
and then move to its mouthparts to be retransmitted.
Causes of morbidity
When the microfilariae migrate to the skin they are a target
for the immune system. White blood cells release
various cytokines that have the effect of damaging the
surrounding tissue and causing inflammation. This kills the
microfilariae but is the cause of the morbidity associated
with this disease.
In the skin this can cause intense itching that leads to the
skin becoming swollen and chronically thickened, a
condition often called lizard skin. The skin may also
become lax as a result of the loss of elastic fibres. Over
time the skin may lose some of its pigment; on dark
skin this gives rise to a condition known as leopard
skin.
The symptom that gives the disease its common name river
blindness is also caused by the immune system's reaction to the
microfilariae. The surface of the cornea is another area
to which the microfilariae migrate, where they are also
attacked by the immune system. In the area that is damaged,
punctate keratitis occurs, which clears up as the
inflammation subsides. However, if the infection is chronic,
scelerosing keratitis can occur, making the affected area
become opaque. Over time the entire cornea may become
opaque, thus leading to blindness.
Treatment and control
The treatment for onchocerciasis is ivermectin (mectizan);
infected people can be treated once every twelve months. The
drug paralyses the microfillariae and prevents them from
causing itching. In addition, whilst the drug does not kill
the adult worm it does prevent them from producing additional
offspring. The drug therefore prevents both morbidity and
transmission.
Since 1988, ivermectin has been provided free of charge by
Merck & Co through the Mectizan Donation Program (MDP).
The MDP works together with ministries of health and
non-governmental development organsations such as the [[World
Health Organisation]] to provide free mectizan to those who
need it in endemic areas.
There are various control programs that aim to stop
onchocerciasis from being a public health problem. The first
was the Onchocerciasis Control Program (OCP), which was
launched in 1974 and at its peak covered 30 million people
in eleven countries. Through the use of larvicide spraying
of fast flowing rivers to control black fly populations and,
from 1988 onwards, the use of ivermectin to treat infected
people, the OCP eliminated onchocerciasis as a public health
problem. The OCP was considered to be a success and came to an
end in 2002. Continued monitoring ensures that
onchocerciasis cannot reinvade the area of the OCP.
In 1992 the
Onchocerciasis Elimination Programme for the Americas
(OEPA) was launched. The OEPA also relies on ivermectin.
In 1995 the
African Programme for Onchocerciasis Control (APOC) began,
covering another nineteen countries and mainly relying upon the
use of ivermectin. Its goal is to set up a community directed
supply of ivermectin for those who are infected. In these
ways, transmission has declined.
External links